Skip to main content
SpringerLink
Log in

Plateletworks®

A Novel Point of Care Platelet Function Screen

  • Diagnostic Profile
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

• Platelet function is critically important in the acute-care settings of cardiopulmonary bypass surgery and percutaneous coronary intervention, which are commonly associated with the adverse vascular events of hemorrhage and thrombosis, respectively.

• To improve outcomes, it has been suggested that patients should be screened for platelet count and function periprocedurally, and therapeutic intervention including the possible use of thrombolytics and adequate anticoagulation or administration of antiplatelet agents, should be utilized.

• Antiplatelet therapy including aspirin (acetylsalicylic acid), the thienopyridines (clopidopgrel), and parenteral anti-glycoprotein (GP) IIb/IIIa agents (abciximab, tirofiban, and eptifibatide) are recognized as clinically important in patients at risk of developing thrombotic events.

• Recently, it has been recognized that empiric therapeutic administration of these agents may be suboptimal in clinical environments because of interpatient variability with regard to platelet count, platelet response, receptor concentration on the platelet, and other factors. Hence there is a clinical need to monitor such therapies on an individual basis.

• Traditional platelet tests including light transmission aggregometry (LTA) are inconvenient for acute diagnostic testing because of the complexity of the test and the requirement for specialty training. Hence, ‘near-patient’ test systems have recently been introduced.

• Plateletworks® is an in vitro diagnostic, point-of-care test platform that has demonstrated utility in monitoring platelet response to all current antiplatelet agents including aspirin and clopidogrel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M, editors. Thrombosis in cardiovascular disorders. Philadelphia (PA): WB Saunders, 1992: 1–16

    Google Scholar 

  2. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Fuster V, Verstraete M, editors. Thrombosis in cardiovascular disorders. Philadelphia (PA): WB Saunders, 1992: 17–39

    Google Scholar 

  3. Sughayer M, Arkin CF. Monitoring coagulation during and after cardiopulmonary bypass surgery. Thromb Hemost 1990; 12(4): 1–7

    Google Scholar 

  4. Steinhubl S, Talley DJ, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) Multicenter Study. Circulation 2001; 103: 2572–8

    Article  PubMed  CAS  Google Scholar 

  5. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680–97

    PubMed  CAS  Google Scholar 

  6. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997: 95; 809–13

    Article  PubMed  CAS  Google Scholar 

  7. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/ IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614–7

    Article  PubMed  CAS  Google Scholar 

  8. Califf RA, Willerson JT. Percutaneous transluminal coronary angioplasty: prevention of occlusion and restenosis. In: Fuster V, Verstraete M, editors. Thrombosis in cardiovascular disorders. Philadelphia (PA): WB Saunders, 1992: 389–408

    Google Scholar 

  9. Anderson HV, Jordan RE, Weisman HF. Concept and clinical application of platelets glycoprotein IIb/IIIa inhibition with abciximab (c7E3 Fab; ReoPro) for the prevention of acute ischemic syndromes. Clin Appl Thromb Hemost 1997; 3(4): 256–66

    Article  Google Scholar 

  10. Anti-Platelet Trialists Collaboration. Collaborative overview of randomized trials of anti-platelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ 1994; 308: 81–91

    Article  Google Scholar 

  11. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC) trial. Am J Cardiol 1995; 75: 559–62

    Article  PubMed  CAS  Google Scholar 

  12. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonist and thrombolytic therapy for acute myocardial information. Thromb Haemost 1997; 78: 214–9

    PubMed  CAS  Google Scholar 

  13. Campbell FW, Addonzio VP. Platelet function alterations during cardiac surgery. In: Ellison N, Jobes DR, editors. Effective hemostasis in cardiac surgery. 1st ed. Philadelphia (PA): WB Saunders, 1988: 85–109

    Google Scholar 

  14. Despotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on-site monitoring of patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107: 271–9

    PubMed  CAS  Google Scholar 

  15. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178–95

    PubMed  CAS  Google Scholar 

  16. Born GVR, Hardisty RM. Platelets. In: Biggs R, editor. Human blood coagulation haemostasis and thrombosis. 2nd ed. London: Blackwell Scientific Publications, 1976: 168–201

    Google Scholar 

  17. Storey RF, Wilcox RG, Hepinstall S. Differential effects of glycoprotein GPIIb/ IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 1998; 98: 1616–21

    Article  PubMed  CAS  Google Scholar 

  18. Podczasy JJ, Lee J, Vucenik I. Evaluation of whole-blood lumiaggregation. Clin Appl Thromb Hemost 1997; 3: 190–5

    Article  Google Scholar 

  19. Dade PFA-100™. Platelet function analyzer [technical information; online]. Available from URL: http://www.dadebehring.com/edbna2/ebusiness/products/productDetail.jsp?PROD_OID=76320&FEATURED_PROD=Y [Accessed 2008 Mar 27]

  20. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99: 620–5

    Article  PubMed  CAS  Google Scholar 

  21. Carville DGM, Schleckser PA, Guyer KE, et al. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 1998; 30(4): 171–7

    PubMed  CAS  Google Scholar 

  22. Lau WC, Waskell LA, Neer CJ, et al. The effect of drugs which are known inducers and inhibitors of human cytochrome P450 3 A on the platelet inhibitory activity of clopidogrel. Am J Cardiol 2002; 39(5): 235A

    Google Scholar 

  23. Lau WC, Walker CT, Ogilby JD, et al. Evaluation of a near patient platelet function assay: performance and clinical utility. Ann Cardiac Anaesth 2002; 5: 33–42

    Google Scholar 

  24. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32–7

    Article  PubMed  CAS  Google Scholar 

  25. Guyer KE, Carville DGM, Lau WC. Platelet protection using the glycoprotein IIb/ IIIa inhibitor tirofiban in a patient with heparin induced thrombocytopenia undergoing aortic valve replacement requiring cardiopulmonary bypass. Point Care 2003; 2(2): 119–24

    Google Scholar 

  26. Lau WC, Gurbel PA, Bliden KP, et al. St John’s wort enhances clopidogrel responsiveness in clopidogrel resistant volunteers and patients by induction of CYP3A4 isoenzyme [abstract no. 1008-121]. J Am Coll Cardiol 2007; 49(9): 343A

    Google Scholar 

  27. Lau WC, Neer CJ, Watkins PB, et al. Clopidogrel non-responders discovered during point-of-care platelet aggregation testing. J Am Coll Cardiol 2003; 41(6) Suppl. A: 1009–117

    Article  Google Scholar 

  28. Lau WC, Hallock L, Carville DGM, et al. The primary in vivo metabolic activation of clopidogrel is by hepatic and not enterocytic cytochrome P450 3A4 isoenzyme [abstract no. 1008-119]. J Am Coll Cardiol 2007; 49(9): 343A

    Google Scholar 

  29. Guyer KE, Carville DGM, Ridgway HR, et al. Point-of-care monitoring for optimal anti-platelet therapy in acute clinical settings. Point Care 2007; 6(3): 209–12

    Google Scholar 

  30. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the ASpirin-induced Platelet EffeCT (ASPECT) study. Circulation 2007; 115: 3156–64

    Article  PubMed  CAS  Google Scholar 

  31. Geske FJ, Guyer KE, Ens G. AspirinWorks®: a new immunologic diagnostic test for monitoring aspirin effect. Mol Diagn Ther 2008; 22(1); 51–4

    Article  Google Scholar 

Download references

Acknowledgments

James Campbell and Helen Ridgway are employees of Helena Laboratories, the manufacturer of Plateletworks®, and David Carville serves as a consultant for the company.

Author information

Authors and Affiliations

  1. Helena Laboratories Corp., 1530 Lindberg Drive, Beaumont, Texas, 77704-0752, USA

    James Campbell & Helen Ridgway

  2. Indiana University, South Bend, Indiana, USA

    David Carville

Authors
  1. James Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen Ridgway
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Carville
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Campbell.

Appendix

Appendix

The following table is a short comparison of available Point of Care platelet function platforms.

Table AI
figure TabA1

Comparison of tests for assessing platelet function

Full size image

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campbell, J., Ridgway, H. & Carville, D. Plateletworks®. Mol Diag Ther 12, 253–258 (2008). https://doi.org/10.1007/BF03256290

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256290

Keywords

Search

Navigation